Volume 9 | May 3, 2023 | View in Browser
Collaborating, connecting, and community are so important to us because these are the hallmarks of a winning team, and what we need to beat osteosarcoma together. Scientists, clinicians, patients, caregivers, industry, and donors all play a key role in moving the ball up the field, closer to our goal. We were inspired by the huge team assembled at AACR, all there to tackle cancer from multiple angles. We are incredibly honored to join the NCI MyPART Network team to join forces on finding treatments for rare cancers. Check out our FACTOR 2023 conference agenda to see the amazing team we've assembled to collaborate on a cure in Atlanta, and our sponsors who make it possible. There are opportunities this month to take advantage of team science funding opportunities from Cancer Grand Challenges and the Samuel Waxman Cancer Research Foundation/Alan B. Slifka Foundation and ICRF. And sometimes a strong team just needs two players, which is the magic of our Ambassador Agents program. Thank you for being part of our team - we are stronger together.
Join us in advancing treatment for osteosarcoma with six scientific panels and three breakout discussion groups addressing Biomarkers for Risk Stratification, Preclinical Models, Comparative Oncology, Local Control, Immunotherapies, and Molecularly Targeted Therapies.
We were so encouraged by all the exciting work and efforts around the world on Making It Better for osteosarcoma patients at the AACR conference this year. Four mini-symposiums and 60 poster presentations on osteosarcoma! Treatment and outcomes have not changed in 40 years, but the activity at AACR gives us hope that will change soon.
MIB Agents will launch our third annual OutBidding Osteosarcoma auction - live at FACTOR 2023, June 22-24 in Atlanta. Have a unique item or experience that can be auctioned off to the highest bidder? Please complete the donation form by May 15th to join us on our mission to OutBid Osteosarcoma. All funds raised will Make It Better for our Osteosarcoma community.
If you have a job posting and you would like it included here, please email email@example.com.
A virtual tumor review board for osteosarcoma, TURBO is open to global clinicians or researchers with an interest in osteosarcoma. Patients and families are welcome to ask their oncologists to present a case on their behalf. Join TURBO to request an invite or submit a case.
Next meeting: May 10th at 5pm ET
ACCELERATE and the 11 members of the ALADDIN consortium have launched a new educational program on strategic and regulatory science in paediatric oncology drug development to foster expertise and strengthen true multi-stakeholder collaboration.
The MIB Agents Ambassador Agents program connects osteosarcoma patients and families to the osteosarcoma survivors and their families. Ambassador Agents have walked the osteosarcoma path and are dedicated to providing support and hope to individuals who are in treatment now.
Our next Ambassador Agent training will be held in-person on June 23rd in Atlanta prior to the FACTOR conference. Email firstname.lastname@example.org to learn more.
MIB Agents is honored to join the NCI MyPART Network as an advocacy partner. The MyPART (My Pediatric and Adult Rare Tumor )network is a group of scientists, patients, family members, advocates, and healthcare providers who want to help find treatments for rare cancers like childhood, teen, and young adult solid rare tumors that have no cures. As an advocacy partner, we look forward to working with MyPART to find patients who may want to join MyPART clinics or trials and sharing important information about rare tumors and share resources for patients and their families.
Nine of cancer’s toughest challenges with up to $25 million in funding for global research teams. One of the challenges this year: Develop therapeutics to target oncogenic drivers of solid tumours in children. The deadline to apply is 22 June 2023, and shortlisted teams will be announced in August 2023. Expressions of Interest are open until 22 June 2023, with international teams invited to apply for up to $25m in funding.
The Samuel Waxman Cancer Research Foundation (SWCRF), Alan B. Slifka Foundation (ABSF) and Israel Cancer Research Fund (ICRF) have issued a joint Request for Applications (RFA) for collaborative applications focused on fusion-positive pediatric sarcomas. Projects must involve collaboration between two research groups — one in North America and one in Israel — with different but complementary expertise. Proposals must justify the partnership through synergistic scientific aims. One successful collaborative project will be awarded $150,000 per year for two years, or a total of $300,000, with each university-based research group receiving $75,000 per year ($150,000 ). The LOI deadline has been extended to June 1.
If you have a trial that is currently enrolling osteosarcoma patients, please email email@example.com.